Can AI be a valuable tool in your fertility journey? Help us find out!
Alife Health and Inception Fertility and its family of brands, including the Prelude Network ™, are partnering in a research study designed to investigate whether the Alife Hera System can help to determine the embryos most suitable for transplant. Using AI algorithms, the Alife Hera System analyzes embryos that embryologists have determined are suitable for transfer and provides a prediction of their likelihood of leading to clinical pregnancy. The study will allow researchers to analyze the impact AI has on embryo selection and help determine if the Alife Hera System can be a valuable tool in aiding families in their fertility journeys. The study will help to advance the field of IVF.
Alife Health and Inception Fertility and its family of brands, including the Prelude Network ™, are partnering in a research study designed to investigate whether the Alife Hera System can help to determine the embryos most suitable for transplant. Using AI algorithms, the Alife Hera System analyzes embryos that embryologists have determined are suitable for transfer and provides a prediction of their likelihood of leading to clinical pregnancy. The study will allow researchers to analyze the impact AI has on embryo selection and help determine if the Alife Hera System can be a valuable tool in aiding families in their fertility journeys. The study will help to advance the field of IVF.
Participant Requirements
An estimated 220 patients will participate in the study. During the study, participants’ embryos will be randomly selected to be evaluated using only traditional methods or traditional methods combined with the Alife Hera System. After this analysis, the embryos will be transferred. The clinical pregnancy rate, defined as a fetal heart rate at 6-8 weeks, will help to determine how valuable the Alife Hera System can be in evaluating and predicting the successful transfer of embryos.
Participant Requirements
An estimated 220 patients will participate in the study. During the study, participants’ embryos will be randomly selected to be evaluated using only traditional methods or traditional methods combined with the Alife Hera System. After this analysis, the embryos will be transferred. The clinical pregnancy rate, defined as a fetal heart rate at 6-8 weeks, will help to determine how valuable the Alife Hera System can be in evaluating and predicting the successful transfer of embryos.
During the Study:
No extra visits are required for participation in this study, with patients and embryos undergoing routine evaluations that are commonly part of the IVF journey.
Participation is entirely voluntary.
Participants can withdraw at any point during the study.
During the Study:
No extra visits are required for participation in this study, with patients and embryos undergoing routine evaluations that are commonly part of the IVF journey.
Participation is entirely voluntary.
Participants can withdraw at any point during the study.
Sign up!
If you’re interested in participating in the LOTUS study and advancing the field of IVF, please complete this online registration.
Inception Fertility is the largest network of fertility centers in North America. Its family of brands is committed to helping aspiring parents build modern families while pursuing their fertility journeys on their own terms. Built by patients for patients, Inception seeks to set the highest bar for patient experience and outcomes through advanced reproductive science and technology.
©2022 Inception Fertility, Inc. All rights reserved.